Intriguingly, L-MSCs (lymphoma-derived MSCs) induce stronger direction of monocytes/macrophages than BM-MSCs (bone-marrow-derived MSCs), and this activation may be increased by CCR2 ligands, which promote tumour growth in vivo [23]. The gene discussed is CCR2; the disease is lymphoma.